ImmusanT, Inc., a Cambridge, Mass.-based biotechnology company focused on restoring tolerance to gluten in celiac disease, has raised $20m in Series A financing from Vatera Healthcare Partners LLC.
The company intends to use the funding to advance development of its immunotherapeutic vaccine Nexvax2®, a companion diagnostic and monitoring tool for celiac disease, to the point of demonstrating proof-of-concept.
ImmusanT expects to initiate the next clinical trial in early 2012.
Led by Founder, President and CEO Leslie J. Williams, and Scientific Founder and Chief Scientific Officer Dr. Bob Anderson, the company is also developing a proprietary whole-blood functional T-cell test for use both as a standalone diagnostic for celiac disease and as a monitoring tool for the therapeutic.
FinSMEs
14/12/2011